US9840156023 - Common Stock
XENETIC BIOSCIENCES INC
NASDAQ:XBIO (5/1/2024, 7:00:03 PM)
4.135
-0.17 (-3.84%)
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing its immune-oncology technologies addressing hard to treat cancers. The firm's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. The firm is also developing its personalized Chimeric Antigen Receptor (CAR) T platform technology, XCART, to develop cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The company is also focused on developing its proprietary drug delivery platform, PolyXen, which uses the biological polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins.
XENETIC BIOSCIENCES INC
945 Concord St.
Framingham MASSACHUSETTS 01701
P: 17817787720
CEO: Jeffrey F. Eisenberg
Employees: 4
Website: https://www.xeneticbio.com/
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xenetic Biosciences (NASDAQ:XBIO) just reported results for the fourth quarter ...
Xenetic Biosciences (XBIO) has announced it will effect a one-for-ten reverse stock split of its outstanding common stock, effective May 15, 2023.The company expects that upon the...
Here you can normally see the latest stock twits on XBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: